“Pharmacokinetics, Safety, and Tolerability of Oxfendazole in Healthy Adults in an Open Label Phase 1 Multiple Ascending Dose and Food Effect Study.”, Antimicrob Agents Chemother, 2020.
, “Assessing the Impact of a Genomic Classifier on Post-Operative Physician Decision-Making for Prostate Cancer Patients in Contemporary Clinical Management”, in 14th Annual Meeting of the Society of Urologic Oncology (SUO), Bethesda, MD, 2013.
, “Effect of a genomic classifier test on clinical practice decisions for patients with high-risk prostate cancer after surgery.”, BJU Int, vol. 115, no. 3, pp. 419-29, 2015.
, “Effect of a Genomic Classifier Test on Clinical Practice Decisions for Patients with High-Risk Prostate Cancer After Surgery”, BJU Int, 2014.
, “Impact of a Genomic Classifier of Metastatic Risk on Treatment Recommendations Post-Radical Prostatectomy: Report from the DECIDE Study Group”, in American Society of Clinical Oncology Annual Meeting, Chicago IL, 2013.
, “Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group.”, Oncotarget, vol. 4, no. 4, pp. 600-9, 2013.
, “Evaluation of a Genomic-Based Prognostic Test for Metastasis in High-Risk Post-Prostatectomy Patients: Does it Impact Physician Decision Making”, in American Society of Clinical Oncology, Genitourinary Cancers Symposium, Orlando FL, 2013.
, “Impact of a Genomic Classifier of Metastatic Risk on Postoperative Treatment Recommendations for Prostate Cancer Patients: A Report from the DECIDE Study Group”, Oncotarget, vol. 4, pp. 600-609, 2013.
, “Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans.”, J Infect Dis, vol. 211, no. 4, pp. 518-28, 2015.
, “First-in-Human Evaluation of a Hexon Chimeric Adenovirus Vector Expressing HIV-1 Env (IPCAVD 002)”, J Infect Dis, vol. 210, pp. 1052-1061, 2014.
, “First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001).”, J Infect Dis, vol. 207, no. 2, pp. 240-7, 2013.
, “First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine (IPCAVD 001)”, J Infect Dis, vol. 207, pp. 240-247, 2013.
, “First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002).”, J Infect Dis, vol. 210, no. 7, pp. 1052-61, 2014.
, “Induction of HIV-1-Specific Mucosal Immune Responses Following Intramuscular Recombinant Adenovirus Serotype 26 HIV-1 Vaccination of Humans”, J Infect Dis, vol. 211, pp. 518-528, 2015.
, “Density of Upper Respiratory Colonization With Streptococcus pneumoniae and Its Role in the Diagnosis of Pneumococcal Pneumonia Among Children Aged <5 Years in the PERCH Study.”, Clin Infect Dis, vol. 64, no. suppl_3, pp. S317-S327, 2017.
, “Chronic kidney disease after liver transplantation in human immunodeficiency virus/hepatitis C virus-coinfected recipients versus human immunodeficiency virus-infected recipients without hepatitis C virus: results from the National Institutes of Health mu”, Liver Transpl, vol. 19, no. 6, pp. 619-26, 2013.
, “Chronic Kidney Disease (CKD) After Liver Transplantation in HIV/HCV Coinfected Versus HIV/non-HCV Infected Recipients: Results from the NIH Multi-Site Study”, Liver Transpl, vol. 19, pp. 619-626, 2013.
, “Maternal and neonatal outcomes by labor onset type and gestational age.”, Am J Obstet Gynecol, vol. 202, no. 3, pp. 245.e1-245.e12, 2010.
, “Maternal and Neonatal Outcomes by Labor Onset Type and Gestational Age”, Am J Obstet Gynecol., vol. 202, pp. 245.e241-245.e212, 2010.
“Immunologic Predictors of Liver Transplantation Outcomes in HIV-HCV Co-Infected Persons.”, PLoS One, vol. 10, no. 8, p. e0135882, 2015.
, “Islet product characteristics and factors related to successful human islet transplantation from the Collaborative Islet Transplant Registry (CITR) 1999-2010.”, Am J Transplant, vol. 14, no. 11, pp. 2595-606, 2014.
, “Islet Product Characteristics and Factors Related to Successful Human Islet Transplantation From the Collaborative Islet Transplant Registry (CITR) 1999-2010”, Am J Transplant, vol. 14, pp. 2595-2606, 2014.
, “Associations between autofluorescence abnormalities and visual acuity in idiopathic macular telangiectasia type 2: MacTel project report number 5.”, Retina, vol. 34, no. 8, pp. 1630-6, 2014.
, “Associations Between Autofluorescence Abnormalities and Visual Acuity in Idiopathic Macular Telangiectasia Type 2: MacTel Project Report Number 5”, Retina, vol. 34, pp. 1630-1636, 2014.
, “Adverse Reactions in a Phase 1 Trial of the Anti-Malarial DM1157: An Example of Pharmacokinetic Modeling and Simulation Guiding Clinical Trial Decisions.”, Infect Dis Ther, vol. 11, no. 2, pp. 841-852, 2022.
,